Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293384 · ClinicalTrials.gov registry record · NA
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00293384 is a NA study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT00293384, a NA study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying how well giving aprepitant together with granisetron and dexamethasone works in preventing nausea and vomiting in patients receiving cyclophosphamide before undergoing an autologous stem cell transplant.
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Aprepitant
- DRUG Granisetron hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-10 |
| Est. Completion | 2012-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293384
The ClinicalTrials.gov registry entry for NCT00293384 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00293384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293384 about?
NCT00293384 is a clinical study titled "Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant". RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying how well giving aprepitant together with granisetron and dexamethasone works in preventing ...
What is the current status of trial NCT00293384?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2004-10. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00293384?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Aprepitant (DRUG), Granisetron hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00293384?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.